Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Inclusion Criteria: * Confirmed diagnosis of mantle cell lymphoma with CD20 positivity and chromosome translocation t(11;14), (q13;q32) and/or overexpress cyclin D1 in tissue biopsy * Include patients who require treatment (versus watch/wait) * Prior treatment with ibrutinib discontinued for reasons other than progression * Ibrutinib intolerance is defined as unacceptable toxicity where, in the opinion of the investigator, treatment should be discontinued in spite of optimal supportive care as a result of one of the following: * 2 or more grade \>= 2 non-hematological toxicities; OR * 1 or more grade 3 \>= 3 non-hematological toxicity; OR * 1 or more grade 3 neutropenia with infection or fever; OR, * Grade 4 hematologic toxicity which persists to the point that the investigator chose to stop therapy due to toxicity NOT progression * Toxicity must have resolved to =\< grade 1 prior to acalabrutinib dosing * Understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form * Bi-dimensional measurable disease using the Cheson criteria (measurable disease by positron emission tomography \[PET\]-computed tomography \[CT\] scan defined as at least 1 lesion that measures \>= 1.5 cm in single dimension). Gastrointestinal, bone marrow or spleen only patients are allowable * Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less * Absolute neutrophil count (ANC) \> 1,000/mm\^3 * Patients who have bone marrow infiltra…